Cargando…

Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial

BACKGROUND: Androgen deprivation therapy (ADT) combined with docetaxel chemotherapy is the standard treatment for metastatic castration-resistant prostate cancer (mCRPC) patients. However, mCRPC patients are mainly frail elderly men, constantly accompanied by comorbidities and showing poor tolerance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Xiangwei, Chen, Hong, Xu, Duanya, Chen, Xianju, Li, Yamei, Tian, Jun, Wang, Dongwen, Pang, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848813/ https://www.ncbi.nlm.nih.gov/pubmed/35172779 http://dx.doi.org/10.1186/s12885-022-09276-y

Ejemplares similares

Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis
por: Botrel, Tobias Engel Ayer, et al.
Publicado: (2016)

WHICH PATIENTS WILL BENEFIT MOST FROM DOCETAXEL ADDITION TO ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC CASTRATE-SENSITIVE PROSTATE CANCER (MCSPC)?
por: Gamulin, Marija, et al.
Publicado: (2019)

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
por: Uemura, Hiroji, et al.
Publicado: (2021)

Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
por: Ito, Tetsuro, et al.
Publicado: (2018)

The impact of hegemonic masculine ideals on self‐esteem in prostate cancer patients undergoing androgen deprivation therapy (ADT) compared to ADT‐naïve patients
por: Gentili, Caterina, et al.
Publicado: (2022)

Transport of ADT
por: Juha Sakkinen
Publicado: (2006)

ADT and OBSBOX in 2016
por: Valuch, D, et al.
Publicado: (2017)

Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy
por: Min, Kyungchan, et al.
Publicado: (2020)

Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT
por: Ayoub, Zeina, et al.
Publicado: (2022)

The Use of Androgen Deprivation Therapy (ADT) and Chemotherapeutic Agents in New Zealand Men with Prostate Cancer
por: Lawrenson, Ross, et al.
Publicado: (2014)

International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries
por: Liede, Alexander, et al.
Publicado: (2016)

Combining Intra-Tumoral Treg Depletion with Androgen Deprivation Therapy (ADT): Pre-Clinical Activity in the Myc-CaP Model
por: Shen, Ying-Chun, et al.
Publicado: (2017)

ADT fast losses MD
por: Priebe, A, et al.
Publicado: (2013)

Editorial on an international survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries
por: Sternberg, Cora N
Publicado: (2016)

Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer
por: Mahalingam, Devalingam, et al.
Publicado: (2023)

Correction: Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer
por: Mahalingam, Devalingam, et al.
Publicado: (2023)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
por: Li, Qi, et al.
Publicado: (2019)

ADT and RF after LS1
por: Butterworth, A, et al.
Publicado: (2015)

Weniger Corona-Infektionen unter ADT?
por: Bublak, Robert
Publicado: (2020)

Bridging Arrays and ADTs in Recursive Proofs
por: Fedyukovich, Grigory, et al.
Publicado: (2021)

Testosterone as a Biomarker for Quality of Life (QOL) Following Androgen Deprivation Therapy (ADT) and Stereotactic Body Radiotherapy (SBRT)
por: Shah, Sarthak, et al.
Publicado: (2023)

Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/− Docetaxel
por: Carrot, Aurore, et al.
Publicado: (2022)

The LHC Transverse Damper (ADT) Performance Specification
por: Boussard, Daniel, et al.
Publicado: (2000)

Rupture of liver metastasis in high‐volume metastatic prostate cancer patient on androgen deprivation therapy combined with upfront docetaxel chemotherapy
por: Hata, Kenichi, et al.
Publicado: (2022)

Noise studies with new ADT pickups (MD4143)
por: Buffat, Xavier, et al.
Publicado: (2019)

Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers
por: Choi, Erin, et al.
Publicado: (2022)

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.
por: Hilkens, P. H., et al.
Publicado: (1997)

Nail Changes During Docetaxel Containing Combination Chemotherapy
por: Woo, In Sook, et al.
Publicado: (2004)

Trastuzumab–Docetaxel Combination Chemotherapy Induced Severe Onychopathy
por: Sonthalia, Sidharth, et al.
Publicado: (2017)

De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT)
por: Skolarus, Ted A., et al.
Publicado: (2018)

Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model
por: Siewe, Nourridine, et al.
Publicado: (2022)

Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
por: Jang, Ho Seong, et al.
Publicado: (2016)

Emittance growth in collision with optimised ADT settings (MD3291)
por: Buffat, Xavier, et al.
Publicado: (2019)

Active halo control through narrow-band excitation with the ADT
por: Wagner, Joschka, et al.
Publicado: (2016)

ADT and Obsbox in LHC Run 2, Plans for LS2
por: Söderén, M, et al.
Publicado: (2019)

AB17. ADT treatment promotes PCa EMT and metastasis
por: Niu, Yuan-Jie
Publicado: (2014)

Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial
por: Zhao, Xianzhi, et al.
Publicado: (2022)

Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer
por: Chowdhury, Simon, et al.
Publicado: (2019)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Personalized downstaging treatment with ADT, chemotherapy and add-on zimberelimab for very-high-risk clinically localized prostate cancer: A case report
por: Li, Jie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i2l455kpi63almfcg9mh0ljl7i